CORRESPONDENCE

Re: Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma

Bhadrasain Vikram

Correspondence to: Bhadrasain Vikram, M.D., Department of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, 111 E. 210 St., Bronx NY 10467 (e-mail: bvikram{at}montefiore.org).

Calais et al. (1) provide, perhaps, the best evidence yet that adding concomitant chemotherapy to "standard" radiotherapy is beneficial for the patients with oropharyngeal carcinoma. Unfortunately, it is also apparent from their results [see Table 3, B, of (1)] that, even after adding chemotherapy, far too many patients had tumor recurrence, either local (33%), regional (19%), or distant (11%). Although they did not discuss it, their Table 3, C (late toxic effects), is most valuable for considering what may and may not be feasible for further decreasing tumor recurrence. A high incidence of severe cervical fibrosis was observed, which precludes escalation of the external-beam radiotherapy dose and may even warrant a decrease. However, no dose-limiting toxicity related to the primary site was observed, which suggests that higher doses by brachytherapy to the primary site should be delivered for decreasing the rate of recurrence at the primary site (2). Additionally, planned neck dissection may decrease the regional recurrence rate (3). Calais et al. did not state if regional recurrence was more likely among the patients initially presenting with stage N2 or N3 disease than among patients initially presenting with N0 or N1 disease. If such information were available, it may help physicians decide who should undergo neck dissection and who can be spared.

Finally, the low incidence of distant recurrence observed by Calais et al. (with or without chemotherapy), in a group of patients, 76% of whom had clinical N-positive disease, was a pleasant surprise. It was not stated, however, whether the actuarial incidence or distant recurrence was similarly low or not.

REFERENCES

1 Calais G, Alfonsi M, Barder E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–6.[Abstract/Free Full Text]

2 Harrison LB, Lee HJ, Pfister DG, Kraus DH, White C, Raben A, et al. Long-term results of primary radiotherapy with/without neck dissection for squamous cell cancer of the base of tongue. Head Neck 1998;20:668–73.[Medline]

3 Cummings C, Geopfert H, Myers E. Squamous cell carcinoma of the base of the tongue. Head Neck Surg 1986;9:56–9.[Medline]


This article has been cited by other articles in HighWire Press-hosted journals:


             
Copyright © 2000 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement